Benzinga -
- Credit Suisse has raised the price target on Merck & Co Inc (NYSE: MRK) from $120 to $125, with an Outperform rating.
- The 2023 American College of Cardiology conference is expected to be a significant catalyst for Merck, says the analyst.
- The key investor focus will be readouts on March 6 from sotatercept's Phase 3 STELLAR trial for Pulmonary Arterial Hypertension (PAH) and the cholesterol-lowering Phase 2 data from oral PCSK9 (MK-0616).
- KOL expects a ~25-meter improvement in a six-minute walk distance, which should see sotatercept being slotted as a 4L agent add-on to conventional triplet therapy.
- Credit Suisse forecasts a 90% probability of c.$3 billion in peak sales.
- CS's KOL's expectations for Phase 2 data are for a similar level of lowering low-density lipoprotein cholesterol as injectable PCSK9. Tolerability will be key.
- The analyst has increased the POS from 30% to 50% and oral PCSK9 peak sales from $1.3 billion to $5 billion. However, a slow build with a turning point based on CVOT data is expected in 2028.
- Price Action: MRK shares are up 0.06% at $108.64 on the last check Monday.
| Feb 2022 | SVB Leerink | Maintains | Outperform | |
| Jan 2022 | JP Morgan | Maintains | Overweight | |
| Dec 2021 | Daiwa Capital | Initiates Coverage On | Neutral |
View the Latest Analyst Ratings
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.